MSLN and neoplasm: CRISPR/Cas9 technology has also been used to knock out the TGF-β receptor II (TGFBR2) and render anti-MSLN CAR T cells resistant to the adverse effect of TGF-β signaling, thus rescuing their proliferation potential, potency and anti-tumor activity in MM mouse models [69].